Fresenius Continues its Biopharma Momentum with Launch of Subcutaneous Formulation of Tyenne® (tocilizumab-aazg) in the United States
FRESENIUS SE S/ADR (FSNUY)
NASDAQ:AMEX Investor Relations:
fresenius.com/index
Company Research
Source: Business Wire
Tyenne® is the first tocilizumab biosimilar available with both an intravenous and subcutaneous formulation approved by the FDA.The subcutaneous formulation of the tocilizumab biosimilar provides increased access and an affordable treatment option for U.S. patients.Subcutaneous formulation was approved by FDA and is available in a self-administered prefilled syringe and an autoinjector.Third Fresenius Kabi biosimilar in the U.S. and second in its immunology portfolio. LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius, via its operating company Fresenius Kabi, announced today the immediate availability in the U.S. of its biosimilar Tyenne® (tocilizumab-aazg), in a subcutaneous formulation, which will increase access to affordable and cost-effective treatment options for use in the treatment of chronic autoimmune diseases.This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240702082765/en/Tyenne® from Fresenius Kabi is the first to
Show less
Read more
Impact Snapshot
Event Time:
FSNUY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FSNUY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FSNUY alerts
High impacting FRESENIUS SE S/ADR news events
Weekly update
A roundup of the hottest topics